Apollomics announces positive preliminary data of vebreltinib in patients with non-cns met fusion solid tumors from its phase 2 sparta trial

43% overall response rate: six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by recist 1.1 out of 14 patients with solid tumors harboring met gene fusions 43% overall response rate: six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by recist 1.1 out of 14 patients with solid tumors harboring met gene fusions
APLM Ratings Summary
APLM Quant Ranking